New Delhi, April 15 (PTI): Cadila Healthcare and Zydus Pharmaceuticals today said they had entered into a settlement agreement with Depomed Inc in a patent infringement row.
The case is related to Depomed’s neuropathic pain relieving drug Gralise.
Cadila Healthcare and Zydus Pharmaceuticals today announced in a joint statement that “they have entered into a settlement agreement with Depomed” regarding the patent infringement litigation related to Gralise 300mg and 600mg tablets.
The settlement will allow Cadila and Zydus to begin the sale of generic versions of Gralise on January 1, 2024, or earlier under certain circumstances, the company said.
Other terms of the settlement were not disclosed.
“The agreement is subject to review by the US department of justice and the federal trade commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey,” the statement said.
Glenmark Pharmaceuticals has got $5 million as a milestone payment from Sanofi for a new drug to treat chronic auto-immune disorders, taking total payments received till date to $55 million.
The milestone payments are part of a deal worth $613 million, which the Mumbai-based firm signed with the French firm in May 2011, for Sanofi to develop the new drug.
Glenmark, through its Swiss subsidiary, received the payment from Sanofi on a collaboration of its VLA2 (alpha2-beta1) integrin monoclonal antibody, the company said in a statement.
The pharma company has already received from Sanofi $50 million as upfront payment in 2011-12.